Neurobo Pharmaceuticals Stock Performance
| NRBO Stock | USD 2.36 0.01 0.43% |
The company secures a Beta (Market Risk) of 2.6, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurobo Pharmaceuticals will likely underperform. At this point, Neurobo Pharmaceuticals has a negative expected return of -0.59%. Please make sure to verify Neurobo Pharmaceuticals' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Neurobo Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 2.95 | Five Day Return 2.54 | Year To Date Return (41.12) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:8 | Dividend Date 2019-12-31 | Last Split Date 2023-12-21 |
1 | Disposition of 407 shares by Dong-a St Co., Ltd of Neurobo Pharmaceuticals at 3.75 subject to Rule 16b-3 | 09/12/2024 |
2 | Acquisition by Dong-a St Co., Ltd of 2544530 shares of Neurobo Pharmaceuticals at 3.93 subject to Rule 16b-3 | 09/18/2024 |
3 | Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over 1,500 | 09/20/2024 |
4 | Insider Trading | 09/27/2024 |
5 | NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity | 09/30/2024 |
6 | NRBO Positive SAD Part 1 Data MAD Part 2 Results Expected in 1Q25 | 10/01/2024 |
7 | NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH | 11/04/2024 |
8 | Acquisition by Strickland D Gordon of 12500 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 | 11/06/2024 |
9 | NRBO Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 | 11/13/2024 |
10 | NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Companys Focus on Ca... | 11/18/2024 |
| Begin Period Cash Flow | 33.4 M |
Neurobo |
Neurobo Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 369.00 in Neurobo Pharmaceuticals on August 30, 2024 and sell it today you would lose (133.00) from holding Neurobo Pharmaceuticals or give up 36.04% of portfolio value over 90 days. Neurobo Pharmaceuticals is currently does not generate positive expected returns and assumes 4.815% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Neurobo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurobo Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurobo Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurobo Pharmaceuticals, and traders can use it to determine the average amount a Neurobo Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1217
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NRBO |
Estimated Market Risk
| 4.82 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.59 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neurobo Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurobo Pharmaceuticals by adding Neurobo Pharmaceuticals to a well-diversified portfolio.
Neurobo Pharmaceuticals Fundamentals Growth
Neurobo Stock prices reflect investors' perceptions of the future prospects and financial health of Neurobo Pharmaceuticals, and Neurobo Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurobo Stock performance.
| Return On Equity | -1.61 | ||||
| Return On Asset | -0.74 | ||||
| Current Valuation | (1.27 M) | ||||
| Shares Outstanding | 8.62 M | ||||
| Price To Earning | (1.44) X | ||||
| Price To Book | 1.56 X | ||||
| Revenue | 7 K | ||||
| EBITDA | (15.88 M) | ||||
| Net Income | (12.47 M) | ||||
| Cash And Equivalents | 8.85 M | ||||
| Cash Per Share | 9.96 X | ||||
| Total Debt | 203 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.07 X | ||||
| Book Value Per Share | 1.50 X | ||||
| Cash Flow From Operations | (10.8 M) | ||||
| Earnings Per Share | (4.29) X | ||||
| Market Capitalization | 20.25 M | ||||
| Total Asset | 22.78 M | ||||
| Retained Earnings | (108.27 M) | ||||
| Working Capital | 16.55 M | ||||
| Current Asset | 21.62 M | ||||
| Current Liabilities | 11.75 M | ||||
About Neurobo Pharmaceuticals Performance
By examining Neurobo Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Neurobo Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Neurobo Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.55) | (0.57) | |
| Return On Capital Employed | (0.94) | (0.99) | |
| Return On Assets | (0.55) | (0.57) | |
| Return On Equity | (0.75) | (0.78) |
Things to note about Neurobo Pharmaceuticals performance evaluation
Checking the ongoing alerts about Neurobo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurobo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurobo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Neurobo Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Neurobo Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Companys Focus on Cardiometabolic Diseases |
- Analyzing Neurobo Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurobo Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Neurobo Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurobo Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurobo Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurobo Pharmaceuticals' stock. These opinions can provide insight into Neurobo Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.